Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Recursion Pharmaceuticals (RXRX) ended the recent trading session at $5.75, demonstrating a -5.89% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily ...
03 October 2024 This update will cover: Ovarian Function Suppression, Chemotherapy for Advanced Breast Cancer and Biological Therapy for Advanced Breast Cancer For further information on the guideline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback